Under the state’s new drug price transparency law, the Green Mountain Care Board used state Medicaid claims data to assemble a list of drugs whose sticker prices have gone up by 15 percent in one year, or by 50 percent in five years.
As a result of GMCB’s investigation, the attorney general’s office has asked 10 pharmaceutical companies by Oct. 1 to submit information that justifies their prescription price increases to the state.
Below are the 10 drugs being investigated and their rate-of-increase during the last five years. They have been listed alphabetically.
- Abilify — 55.3 percent
- Crestor —75.9 percent
- Doxycycline hyclate —4,787.6 percent
- Enbrel —92.7 percent
- EpiPpen — 205.5 percent
- Humira — 113.8 percent
- Lantus — 89.8 percent
- Latuda — 99.7 percent
- Permethrin — N/A
- Prevacid — 103.3 percent
More articles on finance issues:
CHI to shutter Washington state hospital
5 must-reads on bundled payments
10 statistics and findings on medical debt
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.